VERU DENNISON T 4
4 · Brickell Biotech, Inc. · Filed Sep 17, 2020
Insider Transaction Report
Form 4
VERU DENNISON T
Director
Transactions
- Award
Stock Option (right to buy)
2020-09-15+60,000→ 60,000 totalExercise: $0.80Exp: 2030-09-15→ Common Stock (60,000 underlying) - Award
Common Stock
2020-09-15$0.81/sh+13,580$11,000→ 20,810 total - Gift
Common Stock
2020-09-14−19,642→ 7,230 total - Purchase
Common Stock
2020-09-15$0.81/sh+15,355$12,416→ 36,165 total - Purchase
Common Stock
2020-09-16$0.80/sh+14,645$11,758→ 50,810 total
Footnotes (4)
- [F1]On September 15, 2020, the reporting person was granted 13,580 restricted stock units ("RSUs") in lieu of a portion of cash compensation as a director of Brickell Biotech, Inc. The RSUs are scheduled to vest on December 31, 2020 and will be settled in the form of one share of common stock for each RSU.
- [F2]Represents the purchase of 15,355 shares in multiple transactions, ranging in price from $0.80 to $0.8153 per share, resulting in a weighted average purchase price of $0.8086. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range.
- [F3]Represents the purchase of 14,645 shares in multiple transactions, ranging in price from $0.80 to $0.81 per share, resulting in a weighted average purchase price of $0.8029. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price within the range.
- [F4]The stock options will vest 25% on September 15, 2021, and the remainder will vest in equal monthly installments over the following three years.